2024
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, Marino M, Marom E, Putora P, Singh N, Suárez F, Rami-Porta R, Detterbeck F, Eberhardt W, Asamura H, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee M. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2024, 19: 786-802. PMID: 38320664, DOI: 10.1016/j.jtho.2024.01.019.Peer-Reviewed Original ResearchM1c patientsClassification of non-small cell lung cancerNon-small cell lung cancerLung Cancer Staging ProjectMultivariable-adjusted Cox proportional hazards regressionKaplan-Meier methodCell lung cancerCox proportional hazards regressionOrgan systemsProportional hazards regressionM1b categoryM1c categoryMetastatic categoriesMultiple metastasesMetastatic lesionsOverall survivalTNM classificationCurrent tumorLung cancerM categoryHazards regressionM descriptorsDecreased prognosisPotential confoundersMetastasis
2021
Pretreatment Invasive Nodal Staging in Lung Cancer Knowledge, Attitudes, and Beliefs Among Academic and Community Physicians
Henderson LM, Farjah F, Detterbeck F, Smith RA, Silvestri GA, Rivera MP. Pretreatment Invasive Nodal Staging in Lung Cancer Knowledge, Attitudes, and Beliefs Among Academic and Community Physicians. CHEST Journal 2021, 161: 826-832. PMID: 34801593, PMCID: PMC9069181, DOI: 10.1016/j.chest.2021.11.010.Peer-Reviewed Original ResearchConceptsInvasive nodalGuideline adherenceGuideline recommendationsNodal stagingTreatment decisionsThoracic surgeonsNon-small cell lung cancerCell lung cancerBetter patient outcomesAppropriate treatment decisionsLung cancer knowledgeLack of evidenceChest PhysiciansTreatment delayCancer knowledgeLung cancerPatient anxietyPatient outcomesCommunity physiciansAmerican CollegeMost physiciansInsufficient evidenceRoutine practiceWeb-based surveyMultilevel interventionsRates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion size
2020
Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report. CHEST Journal 2020, 158: 406-415. PMID: 32335067, PMCID: PMC7177089, DOI: 10.1016/j.chest.2020.04.020.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCHEST Expert Panel ReportCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicExpert Panel ReportPotential exposureManagement of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiology Imaging Cancer 2020, 2: e204013. PMID: 33778716, PMCID: PMC7233408, DOI: 10.1148/rycan.2020204013.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicPotential exposureGuideline recommendationsSurveillance imaging
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2017
Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System
Dhanasopon AP, Salazar MC, Hoag JR, Rosen JE, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System. The Annals Of Thoracic Surgery 2017, 104: 1829-1836. PMID: 29074151, DOI: 10.1016/j.athoracsur.2017.06.073.Peer-Reviewed Original ResearchConceptsLung cancer staging systemCancer (AJCC) staging systemPneumonectomy patientsLung cancerMortality riskStage IStaging systemLobectomy patientsCox modelNon-small cell lung cancerMultivariable Cox modelNational Cancer DatabaseTreatment-naive patientsOverall survival curvesCell lung cancerLung cancer patientsBenefits of treatmentHigher mortality riskStage-specific survivalRight pneumonectomyLeft pneumonectomyCancer patientsCancer DatabaseInclusion criteriaPneumonectomyThe Significance of Upfront Knowledge of N2 Disease in Non‐small Cell Lung Cancer
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. The Significance of Upfront Knowledge of N2 Disease in Non‐small Cell Lung Cancer. World Journal Of Surgery 2017, 42: 161-171. PMID: 28799084, DOI: 10.1007/s00268-017-4165-6.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerUnsuspected N2 diseaseIII-N2 non-small cell lung cancerN2 diseaseCell lung cancerSurgical resectionAdjuvant chemotherapyAdjuvant therapyOverall survivalPathologic stageLung cancerMultivariate analysisCurative-intent surgical resectionStage IIIA NSCLCHigher comorbidity scoreNational Cancer DatabaseIndependent risk factorKaplan-Meier analysisCN2 diseaseIIIA NSCLCComorbidity scoreCancer DatabaseRisk factorsRetrospective analysisRadiation therapyIndications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT
Gao SJ, Kim AW, Puchalski JT, Bramley K, Detterbeck FC, Boffa DJ, Decker RH. Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT. Lung Cancer 2017, 109: 36-41. PMID: 28577947, DOI: 10.1016/j.lungcan.2017.04.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungClinical Decision-MakingDiagnostic ImagingFemaleHumansLung NeoplasmsMaleMediastinumMiddle AgedNeoplasm MetastasisNeoplasm StagingPatient SelectionPositron Emission Tomography Computed TomographyPractice Guidelines as TopicRetrospective StudiesConceptsOccult N2 diseaseOccult N2 metastasesGround-glass componentInvasive mediastinal stagingCurative-intent therapyT2 tumorsN2 metastasisPET-CTInvasive stagingN2 diseaseT1 tumorsNegative predictive valueMediastinal stagingEarly non-small cell lung cancerExact testPredictive valueSolid tumorsNon-small cell lung cancerClinical stage I NSCLCN2 lymph nodesNode-negative NSCLCOccult nodal involvementPure-solid tumorsStage I NSCLCT1-2N0 disease
2016
Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumorsTiming of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rateLung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. Journal Of Thoracic Oncology 2016, 11: 1121-1131. PMID: 27103511, DOI: 10.1016/j.jtho.2016.03.023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseYounger patientsOlder patientsLung cancerRelative survivalStage IAdvanced stage non-small cell lung cancerCell lung cancerYears of ageAggressive therapyAggressive treatmentOverall survivalPatient demographicsPrimary outcomeTreatment patternsTumor characteristicsNSCLC casesPatientsStage IIIDetailed stagingSurvival informationOlder groupDistinct subsetsCancerLobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer
Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2016, 152: 44-54.e9. PMID: 27131846, DOI: 10.1016/j.jtcvs.2016.03.060.Peer-Reviewed Original ResearchConceptsStage I lung cancerStereotactic body radiotherapyI lung cancerNational Cancer DatabaseClinical stage I lung cancerNon-small cell lung cancerCell lung cancerBody radiotherapyHealthy patientsLung cancerCancer DatabaseClinical stage I non-small cell lung cancerStage I non-small cell lung cancerBetter outcomesEarly-stage non-small cell lung cancerPatient healthCox proportional hazards modelComorbidity-free patientsClinical stage IPropensity-matched analysisProportional hazards modelLong-term survivalHealth-related reasonsStereotactic patientsT1N0M0 tumorsThe Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database
Rosen JE, Keshava HB, Yao X, Kim AW, Detterbeck FC, Boffa DJ. The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2016, 101: 1850-1855. PMID: 27041452, DOI: 10.1016/j.athoracsur.2016.01.077.Peer-Reviewed Original ResearchConceptsOperable non-small cell lung cancerNon-small cell lung cancerNational Cancer DatabaseUntreated NSCLC patientsClinical stage ICell lung cancerNSCLC patientsNatural historyStage ILung cancerCancer DatabaseUntreated non-small cell lung cancerIIIA non-small cell lung cancerMultivariable Cox regression modelsLarge cell histologyNatural history cohortOperable NSCLC patientsCox regression modelMedian survivalUntreated patientsCell histologyMeier estimatesSurgical resectionClinical stageSquamous cellsAdjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe
Salazar MC, Rosen JE, Arnold BN, Thomas DC, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe. Journal Of Thoracic Oncology 2016, 11: 1090-1100. PMID: 27013407, DOI: 10.1016/j.jtho.2016.03.009.Peer-Reviewed Original ResearchConceptsAdditional tumor nodulesAdjuvant chemotherapyT3 tumorsSame lobeTumor nodulesPostoperative chemotherapyOverall survivalSurgical resectionSurvival advantageNon-small cell lung cancerNational Cancer Data BaseNon-small cell lungAdditional pulmonary nodulesAdjuvant chemotherapy subgroupSurvival of patientsCell lung cancerSeparate tumor nodulesChemotherapy subgroupPrimary outcomeCell lungLung cancerChemotherapyCox modelRelative survivalPatients
2015
Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm
Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Annals Of Surgical Oncology 2015, 23: 638-645. PMID: 26474557, DOI: 10.1245/s10434-015-4902-8.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyComorbidityFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPneumonectomyPrognosisSex FactorsSurvival RateYoung AdultConceptsNon-small cell lung cancerAdjuvant chemotherapyNational Cancer Data BaseNon-small cell lungCharlson-Deyo scorePretreatment prognostic factorsCell lung cancerCD scoresGroup of womenGroup of menConclusionsAdjuvant chemotherapySurvival benefitT2 tumorsPrognostic factorsDistant metastasisWomen 65Cell lungLung cancerNSCLC tumorsImproved outcomesChemotherapySurgeryPatientsWomenSurvivalResection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients – A systematic review
DeLuzio MR, Moores C, Dhamija A, Wang Z, Cha C, Boffa DJ, Detterbeck FC, Kim AW. Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients – A systematic review. Pancreatology 2015, 15: 456-462. PMID: 25900320, DOI: 10.1016/j.pan.2015.03.014.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOligometastatic lung cancerCurative-intent resectionLung cancerSystematic reviewMedian survivalSurvival benefitPancreatic metastasisPrimary lung malignancyOverall median survivalSignificant survival benefitCox regression analysisCell lung cancerMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsSurveillance CTPalliative surgeryMetachronous presentationPancreatic headSelect patientsSurgical therapyLung malignancyKaplan-MeierPatientsReporting Items
2014
Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery. The Annals Of Thoracic Surgery 2014, 99: 406-413. PMID: 25528723, DOI: 10.1016/j.athoracsur.2014.09.033.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositive surgical marginsCell lung cancerSurgical marginsR1 resectionNSCLC patientsResidual diseaseLung cancerNational Cancer Data BasePathologic stage IMicroscopic residual diseaseAdministration of chemotherapyOptimal treatment approachStage pIR1 patientsAdjuvant treatmentPostoperative administrationAdjuvant approachIncomplete resectionPostoperative radiationComplete resectionImproved survivalPI patientsPositive marginsSuperior survivalNow or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database
Boffa DJ, Hancock JG, Yao X, Goldberg S, Rosen JE, Kim AW, Moreno A, Detterbeck FC. Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 99: 200-208. PMID: 25440272, DOI: 10.1016/j.athoracsur.2014.08.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseStage III non-small cell lung cancerPreoperative chemotherapyPostoperative chemotherapyLung cancerCancer DatabaseIII-N2 non-small cell lung cancerStage III lung cancerStage III NSCLC patientsTiming of chemotherapyCell lung cancerCox proportional hazardsSeparate Cox modelsNSCLC patientsChemotherapy resultsChemotherapy timingAdjusted comparisonsChemotherapy approachesChemotherapyCox modelProportional hazardsPatientsTumor attributesCStagePredictors of Mortality After Surgical Management of Lung Cancer in the National Cancer Database
Rosen JE, Hancock JG, Kim AW, Detterbeck FC, Boffa DJ. Predictors of Mortality After Surgical Management of Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 98: 1953-1960. PMID: 25443003, DOI: 10.1016/j.athoracsur.2014.07.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseLobectomy/bilobectomyAdverse eventsSurgical resectionMultivariable analysisMale sexFacility volumeLung cancerCancer DatabaseLung cancer surgeryPredictors of mortalityRight-sided tumorsDay of surgeryCell lung cancerStandard of careExtended lengthLarge cancer registryPerioperative outcomesPrimary endpointNSCLC patientsSurgical complicationsWedge resectionSurgical treatmentCancer Registry